FindTrial
Sign In

Mirabegron and Solifenacin versus Mirabegron Over Active Bladder

Efficacy and safety of Mirabegron Monotherapy versus combination of Mirabegron and Solifenacin in patients with Over active bladder- A Randomized Prospective open label observational study at a tertiary care teaching hospital in South India. - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078046
Enrollment
100
Registered
2024-12-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N319- Neuromuscular dysfunction of bladder, unspecified

Interventions

Intervention1: Mirabegron monotherapy: Mirabegron monotherapy vs Mirabegron and Solifenacin. Comparing the effects of both groups by using USS score, OAB score, PVR volume The following effi

Sponsors

Dr Karri Parvathi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Men and women aged 18- 60 years experiencing symptoms of OAB for = 3 months. 2.They should have frequency of micturition on an average = 8 times per 24 h. 3.They should have at least three episodes of urgency, with or without incontinence.

Exclusion criteria

Exclusion criteria: 1.Pregnant / lactating Female 2.Clinically significant bladder outflow obstruction

Design outcomes

Primary

MeasureTime frame
o compare the efficacy of mirabegron 50mg monotherapy versus mirabegron 50mg plus solifenacin 5mg combination therapy in patients of over active bladderTimepoint: at 4 weeks and 12 weeks of treatment—

Secondary

MeasureTime frame
To compare the safety and tolerability of mirabegron 50mg monotherapy with combination of mirabegron 50mg plus solifenacin 5mg.Timepoint: at 4 weeks and 12 weeks of treatment—

Countries

India

Contacts

Public ContactDrCPallavi

Sri Venkateswara Institute Of Medical Sciences- SPMCW

dr.k.parvathireddy@gmail.com9493051069

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026